Interim safety analysis of the DANTE trial: Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma—A randomized, open-label phase II trial of the German Gastric Group at the AIO and SAKK.Nils Homann, Salah‐Eddin Al‐Batran, Albrecht Kretzschmar et al.|Journal of Clinical Oncology|2020Cited by 13
Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma: DANTE, a randomized, open-label phase II trial of the German Gastric Group of the AIO and the SAKKS-E. Al-Batran, Nils Homann, Claudia Pauligk et al.|Annals of Oncology|2019Cited by 8
Safety of perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma: An interim safety analysis of the DANTE, a randomized, open-label phase II trial of the German Gastric Group at the AIO and the SAKK.Salah‐Eddin Al‐Batran, Nils Homann, Sylvie Lorenzen et al.|Journal of Clinical Oncology|2020Cited by 6